Stock Ratings / Health Care / BIAF / options

ISPC (39) ONMD (29) MXCT (30) NRC (65) ⌘ Pro Terminal →

bioAffinity Technologies Inc. (BIAF) Options Positioning, Max Pain & Unusual Sweeps

$3.03 -3.50% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

bioAffinity Technologies Inc. (BIAF) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BIAF)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BIAF)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BIAF.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BIAF)

✓Walkthrough of BIAF's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BIAF // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.87%🛡️ HOLDING TREND SUPPORT

2026-10-30O $3.04H $3.04L $2.86C $3.03VOL 46.4K

RES: $26.68SUP: $2.49SMA50: $6.15SMA200: $19.25

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BIAF Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BIAF Butterfly Map → + Track BIAF →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -34.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BIAF today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BIAF. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BIAF today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BIAF)

Health Care Rank #905 of 1016 ⚔️ ISPC vs BIAF Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BIAF vs. ISPC, ONMD, MXCT, NRC)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, bioAffinity Technologies Inc. (BIAF) ranks #905 by composite RQD confidence (32/100, grade E) and #964 by equity capitalization ($3.9M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with BIAF at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BIAF ACTIVE bioAffinity Technologies Inc.	E	32/100	—	—	-35.0%	-3.50%	$3.9M	Benchmark Subject
ISPC iSpecimen Inc.	D-	39/100	—	11.2%	-35.0%	-9.35%	$2.0M	/ispc-vs-biaf →
ONMD OneMedNet Corp (Class A)	E	29/100	—	-30.0%	-35.0%	-2.02%	$26.3M	/onmd-vs-biaf →
MXCT MaxCyte Inc.	E	30/100	—	96.0%	-27.1%	+1.17%	$178.5M	/mxct-vs-biaf →
NRC NRC Health	C	65/100	44.8x	—	21.0%	+0.09%	$519.6M	/nrc-vs-biaf →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001712762

In its most recent audited fiscal period (FY2025, filed 2025-12-31), bioAffinity Technologies Inc. (BIAF) reported GAAP revenue of $6.2M (-34.2% vs. FY2024 revenue of $9.4M , and +143.3% cumulative change since FY2023) , GAAP net income of -$14.9M, operating cash flow of -$9.3M, and free cash flow of -$9.4M (-27.9% YoY). On the balance sheet, BIAF closed FY2025 with $11.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.2M	-$14.9M	-$9.3M	-$9.4M	$11.0M	—
FY2024 (FY)	2024-12-31	$9.4M	-$9.0M	-$7.3M	-$7.3M	$6.5M	—
FY2023 (FY)	2023-12-31	$2.5M	-$7.9M	-$6.0M	-$6.0M	—	—

3. BIAF Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BIAF stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, bioAffinity Technologies Inc. (NASDAQ: BIAF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.03 (-3.50% 1D, market cap $3.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BIAF ranks #905 in composite RQD confidence.

How does BIAF compare to ISPC and ONMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), BIAF carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ISPC (iSpecimen Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $2.0M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $26.3M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BIAF?

Per BIAF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001712762), bioAffinity Technologies Inc. generated $6.2M in revenue (-34.2% YoY), -$14.9M in net income, and -$9.4M in free cash flow against $11.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BIAF trading relative to its 50-day, 200-day, and 52-week technical levels?

BIAF last traded at $3.03 (-3.50% on volume of 326,533 shares), positioning the stock -50.73% below its 50-day simple moving average ($6.15) and -84.26% below its 200-day simple moving average ($19.25). Across its 52-week range of $2.66 to $80.70, BIAF sits at the 0.5% percentile with a 14-day RSI of 34.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.65 to $3.41).